(NYSE: RCUS) Arcus Biosciences's forecast annual revenue growth rate of -2.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Arcus Biosciences's revenue in 2026 is $100,000,000.On average, 16 Wall Street analysts forecast RCUS's revenue for 2026 to be $10,565,455,293, with the lowest RCUS revenue forecast at $9,454,423,715, and the highest RCUS revenue forecast at $12,321,996,793. On average, 16 Wall Street analysts forecast RCUS's revenue for 2027 to be $8,011,781,754, with the lowest RCUS revenue forecast at $0, and the highest RCUS revenue forecast at $24,643,993,586.
In 2028, RCUS is forecast to generate $15,353,719,171 in revenue, with the lowest revenue forecast at $4,955,868,953 and the highest revenue forecast at $38,387,897,692.